WEBINAR: Responding to ICER’s Tardive Dyskinesia Report

November 16, 2017 @ 12:00 pm – 1:00 pm

The Institute for Clinical and Economic Review has concluded that VMAT2 inhibitors for the treatment of tardive dyskinesia “far exceed” their cost-effectiveness thresholds. The analysis could impact formularies, cost-sharing and patient access.

Please join us for a webinar to discuss this issue further.

About AfPA Digital

The Alliance for Patient Access is a national network of physicians dedicated to ensuring patient access to approved therapies and appropriate clinical care.
Back to Top